Stock Research: OPKO Health

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

OPKO Health

NasdaqGS:OPK US68375N1037
37
  • Value
    67
  • Growth
    15
  • Safety
    Safety
    45
  • Combined
    20
  • Sentiment
    59
  • 360° View
    360° View
    37
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. It operates in pharmaceutical and diagnostics industries, with key pharmaceutical products like Somatrogon (NGENLA) and Rayaldee, and clinical laboratory operations through BioReference. Its pharmaceutical operations are in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, and the United States. In the last fiscal year, the company had a market cap of $1071 millions, profits of $219 millions, revenue of $713 millions, and 2997 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock OPKO Health are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for OPKO Health. The consolidated Sentiment Rank has a good rank of 59, which means that professional investors are more optimistic about the stock than for 59% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 67 or better than 67% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 45, meaning that the share price of OPKO Health is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 15. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
45 41 44 18
Growth
15 57 67 1
Safety
Safety
67 86 49 61
Sentiment
59 49 42 13
360° View
360° View
37 77 38 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
95 95 95 95
Opinions Change
77 50 50 50
Pro Holdings
n/a 51 44 3
Market Pulse
4 10 7 4
Sentiment
59 49 42 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
45 41 44 18
Growth
15 57 67 1
Safety Safety
67 86 49 61
Combined
20 82 10 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
1 1 1 1
Price vs. Earnings (P/E)
22 23 31 25
Price vs. Book (P/B)
74 84 85 79
Dividend Yield
1 1 1 1
Value
45 41 44 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
14 10 6 1
Profit Growth
1 76 80 38
Capital Growth
44 28 75 4
Stock Returns
47 93 85 63
Growth
15 57 67 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
69 85 82 80
Refinancing
90 94 43 45
Liquidity
9 9 15 40
Safety Safety
67 86 49 61

Similar Stocks

Discover high‑ranked alternatives to OPKO Health and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.